The Top Biopharma Calendar Events to Watch Going Into 2020
Here, 24/7 Wall St. has included a calendar of a few of the biggest clinical trial and FDA updates to watch for going into 2020.
All Work
Chris Lange
Why This Duchenne Muscular Dystropy Deal Could Be Huge
Sarepta Therapeutics shares made a handy gain to start the week after it announced a licensing agreement with Roche for its investigational gene therapy for Duchenne muscular dystrophy.
Why This Schizophrenia Treatment Approval Is Such a Big Deal
Intra-Cellular Therapy shares practically doubled on Monday after the firm announced that the FDA has approved Caplyta for the treatment of schizophrenia in adults
Meet the Biggest and Best Blockchain ETFs of 2019
Although the hype for the blockchain has subsided recently, the potential for the technology is touted as being nearly unlimited. In the course of choosing where to invest for this theme specifically, there are…
The First Ebola Vaccine Has Been Approved in the US
NewLink Genetics and Merck shares made handy gains on Friday after it was announced that the FDA has granted approval to Ervebo, the Zaire Ebola virus vaccine V920.
Is Stealth Bio Done After Mitochondrial Myopathy Study?
Stealth Bio shares were absolutely crushed on Friday after the firm announced results from its late-stage study in patients with primary mitochondrial myopathy (PMM). Specifically, the top-line results are coming from the Phase 3…
Carnival Sails Away With Q4 Earnings
Carnival shares rallied after it reported better than expected quarterly results with rosy earnings guidance late on Thursday.
Micron Cruises By With Q1 Earnings
Micron released better than expected fiscal first-quarter financial results after markets closed Wednesday.
What to Expect When Nike Reports Thursday
Nike is scheduled to release its fiscal first-quarter financial results after the markets close on Tuesday, and analysts are looking for solid year-over-year growth.
Meet the Newest Collaboration in the Fight Against Sickle Cell Disease
Syros Pharma and Global Blood Therapeutics shares were on the move on Wednesday after the companies announced a collaboration to develop and commercialize novel therapies for sickle cell disease and beta thalassemia.
What to Watch When Micron Reports After the Close
Micron is scheduled to release its fiscal first-quarter financial results after the closing bell on Wednesday.
Is Solid Biosciences in Trouble After This Duchenne Muscular Dystrophy Update?
Solid Biosciences shares jumped on Wednesday after the firm provided an update from its midstage study in Duchenne muscular dystrophy.
Amazon Rolls Out Free Return Policy Ahead of Christmas
Just in time for Christmas, Amazon announced that it is making buying—and returning—gifts on its platform even easier.
Even More Trouble for FedEx After Earnings
FedEx reported disappointing quarterly results and lowered its guidance after the markets closed on Tuesday, and shares dipped in the after-hours.
What to Watch When Micron Reports Wednesday
Micron Technology is set to report its most recent quarterly results after the markets close on Wednesday, and expectations are very different than a year ago.
Why This Multiple Sclerosis Study’s Positive Results May Not Be Enough
Adamas Pharma shares dropped sharply on Tuesday after the firm reported results from its late-stage multiple sclerosis study.
Why Accelerated Approval Could Be Huge for This Ovarian Cancer Study
ImmunoGen shares jumped on Tuesday after the FDA advised that a new single-arm study in platinum-resistant ovarian cancer could support accelerated approval.
What’s Next for the Proteostasis Cystic Fibrosis Pipeline
Proteostasis shares were absolutely crushed on Tuesday after the firm announced midstage data from its cystic fibrosis study. What comes next?
What to Expect When FedEx Reports After the Close
FedEx is scheduled to release its fiscal second-quarter financial results after the markets close on Tuesday.
Will This Dementia Treatment Be a Big Hit After FDA Decision?
Prevail Therapeutics shares jumped early on Tuesday after the firm announced that the FDA has granted Orphan Drug designation for its dementia treatment.